Tech Center 1600 • Art Units: 1625
This examiner grants 60% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18449800 | TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND GDC-0077 | Non-Final OA | Genentech, Inc. |
| 18277748 | UNSYMMETRIC LINEAR CARBONATE AND METHOD FOR PREPARING THEREOF | Non-Final OA | LG CHEM, LTD. |
| 17912129 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING SAME | Non-Final OA | LG CHEM, LTD. |
| 17642495 | KDM INHIBITORS AND USES THEREOF | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18476916 | METHODS OF TREATING HIDRADENITIS SUPPURATIVA | Non-Final OA | AbbVie Inc. |
| 17999408 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHOD OF USE THEREOF | Non-Final OA | Baylor College of Medicine |
| 18002477 | Methods of Treating, Ameliorating, Shortening Duration, and/or Reversing Symptoms and/or Complications of a Coronavirus Infection | Final Rejection | Yale University |
| 18116952 | COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION | Non-Final OA | ACADEMIA SINICA |
| 18256645 | SUBSTITUTED PYRAZOLYL PIPERIDINE CARBOXYLIC ACIDS | Non-Final OA | BAYER AKTIENGESELLSCHAFT |
| 17914773 | INHIBITORS OF TRPC6 FOR TREATING RESPIRATORY CONDITIONS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18033673 | SALT OF NUCLEOSIDE ANALOG, AND CRYSTAL FORM, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Final Rejection | WUHAN INSTITUTE OF VIROLOGY, CHINESE ACADEMY OF SCIENCES |
| 18017388 | SULFUR-CONTAINING ISOINDOLINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Final Rejection | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. |
| 18316254 | COMPOUNDS AFFECTING PIGMENT PRODUCTION AND METHODS FOR TREATMENT OF BACTERIAL DISEASES | Non-Final OA | Versitech Limited |
| 18286592 | USE OF MITOXANTRONE HYDROCHLORIDE LIPOSOME | Non-Final OA | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD |
| 18266103 | Eyedrops for Treating Scleral Thinning and Screening Method for Therapeutic Agent of Scleral Thinning | Non-Final OA | Tsubota Laboratory, Inc. |
| 17788551 | ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR | Final Rejection | NIPPON SHINYAKU CO., LTD. |
| 18288888 | METHODS FOR TITRATING MITAPIVAT | Non-Final OA | Agios Pharmaceuticals, Inc. |
| 17759265 | COMPOUNDS, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Non-Final OA | Protego Biopharma, Inc. |
| 18006578 | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | Non-Final OA | JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH |
| 18476247 | Use of an alkaloid compound in the preparation of products for the prevention and/or treatment of cardiac damage | Non-Final OA | NORTHWEST INSTITUTE OF PLATEAU BIOLOGY, CHINESE ACADEMY OF SCIENCES |
| 18012260 | AGENTS FOR SENSITIZING SOLID TUMORS TO TREATMENT | Non-Final OA | The United States of America, as Represented by the Secretary, Department of Health and Human Servic |
| 18280774 | COMPOSITIONS AND METHODS FOR TREATING ANEMIA ASSOCIATED WITH A RIBOSOMAL DISORDER | Non-Final OA | Disc Medicine, Inc. |
| 18276569 | SALT OF NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND OR CRYSTAL FORM THEREOF, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Non-Final OA | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. |
| 18262985 | Enhanced Anti-Proliferative and Antitumor Immune Effects of Mitochondria-Targeted Hydroxyurea | Non-Final OA | Aix-Marseille Universite |
| 18269973 | COMPOSITIONS AND METHODS FOR INDUCING DEFECATION | Non-Final OA | Dignify Therapeutics, LLC |
| 18259499 | INHIBITORS OF AUTOTAXIN | Non-Final OA | CADILA HEAL THCARE LIMITED |
| 18253384 | COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH | Non-Final OA | Health Research, Inc. |
| 18142751 | ERIODICTYOL COMPOSITIONS AND METHODS | Non-Final OA | CAS PROPERTIES, LLC |
| 18030050 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | Final Rejection | HUTCHISON MEDIPHARMA LIMITED |
| 18028709 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | Non-Final OA | Japan as represented by Director-General of National Institute of Infectious Diseases |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy